CA 125

,   *

.   *.   *.   *.   *.   .

=ABSTRACT=

The prognostic value of serum CA 125 in endometrial cancer

Jae Eun Chung, Jae Wook Kim*, Young Tae Kim*, Dong Kyu Kim*,
Sei Kwang Kim*, Sung Il Roh, Jung Hyun Cho

Department of Obstetrics and Gynecology, Mizmedi Hospital
Department of Obstetrics and Gynecology, Yonsei University College of Medicne, *
*Seoul, Korea*

Objective : The prognostic value of serum CA 125 sampled before the staging operation and the right CA 125 cut-off level in endometrial cancer was evaluated.

Methods : Medical charts of 119 endometrial cancer patients diagnosed and surgically treated at the Department of Obstetrics and Gynecology, Yonsei University College of Medicine from March 1995 to March 2001 were reviewed. The prognostic value of CA 125 was evaluated by comparing it to other established prognostic factors of endometrial cancer such as myometrial invasion, cervix extension, tumor size, and grossly invasive disease. Enzyme immunoassay (Elecsys 2010; Roche Ltd., Basel, Switzerland) was used for the measurement of serum CA 125.

Results : The level of presurgically taken serum CA 125 level correlated well with the established prognostic factors of endometrial cancer. CA 125 was one of the information that could be obtained prior to the surgical staging for predicting extensive endometrial cancer, and it could be correlated with the 5 year survival. CA 125 20 U/ml had a higher sensitivity and lower false negative rate in predicting extensive endometrial cancer compared to the conventionally used level of CA 125 35 U/ml.

Conclusion : CA 125 has a prognostic value in predicting the extensive endometrial cancer needing lymphadenectomy, therefore it might be included in the baseline study of endometrial cancer for predicting the prognosis and individualizing the treatment modality. CA 125 20 U/ml might be considered as the cut-off level in endometrial cancer for a better sensitivity and false negative rate.

Key Words : Endometrial cancer, CA 125, Prognostic factor

, 1997   ,

37,400   6,400   ,   2,3
.[1]   .

,

,   ,

.   Cancer Antigen 125 (CA 125)   ,

OVCA 433   , Bast   35 U/ml   CA 125
.[4,5]

CA 125

CA 125 [6]

CA 125

. CA 125 ,

, 5 ,

35 U/ml 20 U/ml

, , ,

.

CA 125

Kruskal-Wallis test , Cox proportional
hazard model

, Fisher exact

test 5 .

Student t test , ,

, ,

. P 0.05 .

1995 3 2001 3

119

.

,

, (transvaginal
ultrasonography, TVS) (magnetic resonance
imaging, MRI)

,

CA 125 .

.

,

,

.

,

. 1 3

, 6

, 3 1 .

,

, CA 125 ,

.

CA 125

, ,

.

. CA 125
(enzyme immunoassay; Elecsys 2010, Roche Ltd., Basel,
Switzerland) .

58.8 , 34
69 . 2.4 .
119 72
. 47

. 84.9% , 84.0%
, 63.9% stage 1 ,
64.7% . CA 125 5 U/ml
3014 U/ml . 85.6 U/ml
31.9 U/ml
14 ,
574.3 U/ml (Table 1).

Table 1. Patient characteristics

Characteristics	Number (%)
Age	
Premenopause	18 (15.1)
Postmenopause	101 (84.9)
Histology	
Adenocarcinoma	100 (84.0)
Others[1]	19 (16.0)
Stage	
I	76 (63.9)
II 20 (16.8)	
III-IV 23 (19.3)	
Histologic grade	
I	77 (64.7)
II	23 (19.3)
III	19 (16.0)
Recurrent or persistent disease	
No	92 (77.3)
Yes	27 (22.7)

[1] Others: papillary serous carcinoma 5 cases
clear cell carcinoma 5 cases
mucinous carcinoma 2 cases
undifferentiated 7 cases